Quince Therapeutics
QNCX

Quince Therapeutics (QNCX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Cantor FitzgeraldMaintainedOverweight$70.00Aug 18, 2026
OppenheimerInitiated CoverageOutperform$82.00Jul 29, 2026
Leerink PartnersInitiated CoverageOutperform$4.00Jun 24, 2026
Cantor FitzgeraldInitiated CoverageOverweight$4.00Jun 23, 2026
D. Boral CapitalDowngradedBuy → HoldJan 30, 2026
CitizensDowngradedMarket Outperform → Market PerformJan 30, 2026
D. Boral CapitalMaintainedBuy$5.00Jan 29, 2026
D. Boral CapitalMaintainedBuy$5.00 from $4.00Dec 15, 2025
D. Boral CapitalMaintainedBuy$4.00Nov 13, 2025
D. Boral CapitalMaintainedBuy$4.00Sep 26, 2025
D. Boral CapitalMaintainedBuy$4.00Aug 15, 2025
JMP SecuritiesMaintainedMarket Outperform$8.00 from $9.00Aug 12, 2025
JMP SecuritiesInitiated CoverageMarket Outperform$9.00Aug 5, 2025
D. Boral CapitalMaintainedBuy$4.00Jul 17, 2025
D. Boral CapitalMaintainedBuy$4.00Jun 13, 2025
D. Boral CapitalMaintainedBuy$4.00Jun 4, 2025
D. Boral CapitalMaintainedBuy$4.00 from $12.00Mar 25, 2025
OppenheimerInitiated CoverageOutperform$10.00Mar 24, 2025
D. Boral CapitalMaintainedBuy$12.00Feb 5, 2025
D. Boral CapitalMaintainedBuy$12.00Jan 2, 2025

Frequently asked questions

  • What is the latest analyst rating on QNCX?

    On Aug 18, 2026, Cantor Fitzgerald maintained Quince Therapeutics at Overweight with a price target of $70.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.